A small randomized MRI study found different advantages across onset, recovery, and supplementation. Its abstract and later limitation wording did not agree on which group required more supplementation.
The reported results
Shi and colleagues randomized thirty-nine children to remimazolam and forty to propofol. Sedation success was approximately 92% and 95%, respectively, without a significant difference. Remimazolam induction was slower, while recovery was faster.
Two or more supplemental doses occurred in 23.1% of remimazolam recipients versus 57.5% of propofol recipients in the reported results. That specific comparison should guide any statement about supplementation.
A reporting inconsistency matters
The limitation discussion later refers to a higher supplementation rate with remimazolam, contrary to the abstract’s numbers. The inconsistency should not be silently converted into a clean finding. The paper also acknowledges selected dosing, limited sample, and absent long-term follow-up.
Regression associations involving recovery time do not establish that prolonged recovery caused an earlier adverse event. Temporal order and the construction of those variables need attention.
Use in expert evidence
Report the distinct onset and recovery findings and preserve the conflicting supplementation language. Nonsignificant success rates do not establish formal equivalence, and a short study cannot determine developmental consequences of repeated pediatric sedation.
Source paper
Original analysis of the supplied journal article, identified as PMC12543097.
Leave a Reply